A graduate in Physics from Turin, after 10 years as a researcher at CERN alongside Nobel Prize winner Carlo Rubbia, he founded Advanced Accelerator Applications in 2002, a biotech pioneering Teragnostics in Nuclear Medicine, which he listed on Nasdaq in 2015 and then sold to Novartis in 2018 for $3.9 billion. In 2021, he founded the startup newcleo with the aim of developing small lead-cooled fast reactors for decarbonised energy production.

He invests in innovation, social, education, arts and culture.